Game over as AstraZeneca rejects final $119bn Pfizer bid
This article was originally published in Scrip
AstraZeneca has rejected a final takeover bid of $119bn from Pfizer, marking an end to a month of fevered speculation about the potential merger of the two big pharma groups. "We have rejected Pfizer's final proposal because it is inadequate and would present significant risks for shareholders, while also having serious consequences for the Company, our employees and the life-sciences sector in the UK, Sweden and the US," said AstraZeneca.
You may also be interested in...
Addressing health care inequities, providing a nurturing environment for employees and learning from the pandemic were among the aims expressed by executives surveyed by Scrip.
Digital and telehealth solutions took off during COVID-19 and industry observers expect them to advance still further in the coming year. Coupling enhanced patient experience with rich opportunities to use associated data to enhance product development and health care practice, benefits should accrue to industry, health care practitioners, health systems and patients alike.